Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Wenatchee Valley Medical Center

 

Herceptin + Radiation Therapy for HER2-Positive Resected by Lumpectomy (NSABP B-43)
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

Investigator: Tanya A. Wahl ;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT00769379

Combination Chemotherapy + Radiation Therapy for Stage III/IVA Endometrial Cancer (GOG 0258)
A Randomized Phase III Trialof Cisplatin and Tumor Volume Directional Irradiation Followed By Carboplatin and Paclitaxel Vs.for Optimally Debulked, Advanced Endometrial Carcinoma

Investigator: Benjamin Greer, MD;   Conditions: Endometrial Cancer;    Status: Recruiting;   Study ID: NCT00942357

Radiation vs Brachytherapy for Endometrial Carcinoma (GOG 249)
A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed By Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma

Investigator: Benjamin E. Greer, MD;   Conditions: Endometrial Cancer, Fatigue, Neurotoxicity;    Status: Recruiting;   Study ID: NCT00807768

Carboplatin + Paclitaxel w/wo Bevacizumab After Surgery (GOG 213)
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination With Bevacizumab (NSC #704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreduction Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer

Investigator: Benjamin E. Greer, MD;   Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer;    Status: Recruiting;   Study ID: NCT00565851

Targeted Therapies for Triple Negative Advanced Breast Cancer (6628)
Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel (Abraxane) and Bevacizumab (Avastin) Followed by Maintenance Targeted Therapy With Bevacizumab (Avastin) and Erlotinib (Tarceva)

Investigator: Jennifer Specht, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT00733408

Paclitaxel vs Polyglutamate Paclitaxel (GOG 212)
A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103) (IND# 70177), Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian or Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy

Investigator: Benjamin E. Greer, MD;   Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer;    Status: Recruiting;   Study ID: NCT00108745

Vorinostat + Chemotherapy for CLL or SLL (PSOC-2401)
A Phase I/II Study of Fludarabine (F), Cyclophosphamide ©), Rituximab ®), and Vorinostat (V) Followed by RV Maintenance Therapy in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small LymphoCtic Lymphoma (SLL)

Investigator: John Pagel, MD, PhD;   Conditions: Leukemia, Lymphoma;    Status: Recruiting;   Study ID: NCT00918723

TREC for Relapsed or Refractory Lymphoid Malignancies (PSOC 2502)
A Phase I Trial of Bendamustine/Treanda, Rituxmab, Etoposide, and Carboplatin (TREC) for Patients With Relapsed or Refractory Lymphoid Malignancies

Investigator: Ajay K. Gopal, MD;   Conditions: Lymphoma;    Status: Recruiting;   Study ID: NCT01165112